Number of Participants Who Progressed to Moderate or Severe Disease or Higher Based on the Gates MRI Ordinal Scale Through Day 28;Number of Participants With AEs Resulting in Study Intervention Discontinuation Through Day 35;Number of Participants With Grade 3 and Grade 4 Adverse Events (AEs) Through Day 35;Number of Participants With Serious Adverse Events Through Day 35

Number of Participants Who Progressed to Moderate or Severe Disease or Higher Based on the Gates MRI Ordinal Scale Through Day 28;Number of Participants With AEs Resulting in Study Intervention Discontinuation Through Day 35;Number of Participants With Grade 3 and Grade 4 Adverse Events (AEs) Through Day 35;Number of Participants With Serious Adverse Events Through Day 35

Number of Participants With Grade 3 or Grade 4 Adverse Events (AEs);Proportion of Participants With Disease Progression;Number of Participants With Serious Adverse Events (SAEs);Number of Participants With AEs Leading to Study Discontinuation

Number of Participants With Grade 3 or Grade 4 Adverse Events (AEs);Proportion of Participants With Disease Progression;Number of Participants With Serious Adverse Events (SAEs);Number of Participants With AEs Leading to Study Discontinuation